Nanomedicine for Inflammatory Diseases
Nanomedicine for Inflammatory Diseases is a cutting-edge resource for clinicians and scientists alike, working at the intersection of development and clinical therapeutics. This text is ideal for graduate level courses in nanomedicine, translational medicine, or inflammatory disease. This book is a progressive hallmark in translational medicine as it unites clinicians treating inflammatory disease with scientists developing experimental nanomedicine therapeutics. The commonality is made through a translational nanomedicine expert – bridging the gap between the laboratory benchtop and the clinical bedside.
Table of Contents
Part I • Introduction: Introduction
to Inflammatory Disease,
1 • FUNDAMENTALS OF IMMUNOLOGY
2 • PRINCIPLES OF NANOMEDICINE
3 • NANOTOXICITY
4 • TRANSLATIONAL NANOMEDICINE
Part II • Introduction: Primary
5.1 • BIOLOGY AND CLINICAL TREATMENT
OF INFLAMMATORY BOWEL DISEASE
5.2 • NANOTHERAPEUTICS FOR
INFLAMMATORY BOWEL DISEASE
5.3 • BRIDGING THE GAP BETWEEN
THE BENCH AND THE CLINIC:
INFLAMMATORY BOWEL DISEASE
6.1 • THE BIOLOGY AND CLINICAL
TREATMENT OF MULTIPLE SCLEROSIS
6.2 • NANOTHERAPEUTICS FOR MULTIPLE
6.3 • BRIDGING THE GAP BETWEEN THE
BENCH AND THE CLINIC
7.1 • THE BIOLOGY AND CLINICAL
TREATMENT OF ASTHMA
7.2 • NANOTHERAPEUTICS FOR ASTHMA
7.3 • BRIDGING THE GAP BETWEEN THE
BENCH AND THE CLINIC: ASTHMA
Part III • Introduction:
The Emerging Role
in Common Diseases
8 • NEURODEGENERATIVE DISEASE
9 • CANCER
10 • DIABETES
11 • CONCLUDING REMARKS
Dr. Lara Scheherazade Milane recently joined Burrell College of Osteopathic Medicine (Las Cruces, New Mexico) as founding faculty in the Biomedical Sciences Department and is the Director of Online Programing. Dr. Milane received her training as an NCI/NSF Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane has a PhD in Pharmaceutical Science with specializations in Nanomedicine and Drug Delivery Systems (Northeastern University, Boston, MA). She also received her MS in Biology and BS in Neuroscience from Northeastern University.
Dr. Milane’s research interests are in cancer biology, mitochondrial medicine, and translational nanomedicine. Dr. Milane is interested in developing a library of clinically translatable targeted nanomedicine therapies for cancer treatment. She teaches in the medical program and in the post-baccalaureate program. Dr. Milane is an advocate for women in the sciences and is a pioneer for outreach. Dr. Milane has 18 peer reviewed journal publications, 3 book chapters, and 3 white papers.
Dr. Mansoor Amiji is currently the University Distinguished Professor in the Department of Pharmaceutical Sciences and Co-Director of Northeastern University Nanomedicine Education and Research Consortium (NERC) at Northeastern University in Boston, MA. NERC oversees a doctoral training program in Nanomedicine Science and Technology that was co-funded by the National Institutes of Health (NIH) and the National Science Foundation (NSF). Dr. Amiji received his BS degree in pharmacy from Northeastern University in 1988 and a PhD in pharmaceutical sciences from Purdue University in 1992.
His research is focused on development of biocompatible materials from natural and synthetic polymers, target-specific drug and gene delivery systems for cancer and infectious diseases, and nanotechnology applications for medical diagnosis, imaging, and therapy. His research has received over $18 million in sustained funding from the NIH, NSF, private foundations, and the pharmaceutical/biotech industries.
Dr. Amiji teaches in the professional pharmacy program and in the graduate programs of Pharmaceutical Science, Biotechnology, and Nanomedicine. He has published six books and over 200 book chapters, peer-reviewed articles, and conference proceedings. He has received a number of honors and awards including the Nano Science and Technology Institute’s Award for Outstanding Contributions towards the Advancement of Nanotechnology, Microtechnology, and Biotechnology, American Association of Pharmaceutical Scientists (AAPS) Meritorious Manuscript Award, Controlled Release Society’s (CRS) Nagai Award, and the AAPS and CRS Fellowships.